




Contents lists available at ScienceDirect

Toxicon

journal homepage: www.elsevier.com/locate/toxicon

Editorial: Toxins 2017



This special supplement of *Toxicon* compiles the podium, platform, and poster abstracts submitted for the international conference "TOXINS: Basic Science and Clinical Aspects of Botulinum and other Neurotoxins", to be held in Madrid, Spain, January 18–21, 2017.

Since the previous Toxins meeting in 2015, there have been significant advances in the basic and clinical science and applications of botulinum neurotoxins (BoNTs) in a wide array of established and emerging indications. Toxins 2017 will provide critical updates to participants on these developments and new knowledge.

Topics that are addressed in the abstracts appearing in this supplement include:

- The latest developments in understanding of the structure, pharmacology, and function of BoNTs
- Research aimed at development of novel countermeasures to BoNTs
- Evolution of novel BoNT molecules and formulations
- Recent developments in the clinical trials of BoNTs

- Updates on the use of BoNTs for headache and other pain syndromes, genitourinary conditions, spasticity, cerebral palsy, dystonias and movement disorders, aesthetic and dermatologic uses, and investigational uses
- Advances in knowledge regarding optimizing BoNT therapy (ie, dosing paradigms and methods of localization) and assessing the outcomes of treatment.

We hope you find this supplement to be a valuable resource in furthering your research or clinical practice in the field of botulinum neurotoxins.

Joseph Jankovic, INA President
Baylor College of Medicine, Houston, TX, United States

Alberto Albanese, INA Past President
Università Cattolica del Sacro Cuore, Milan, Italy

Available online 23 November 2016